Polyrizon Ltd. (NasdaqCM: PLRZ)
Health Care · Biotechnology · IL
$11.66
+6.19% today · +77.7% 1Y
Polyrizon Ltd. (NasdaqCM: PLRZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.55M and employs 6 people.
Over the last twelve months the share price has gained 77.7%, trading between 2.88 and 18.20.
Tweenvest scores Polyrizon Ltd. across four factors: quality 30/100. Its strongest factor is quality.
PLRZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $18.20
- 52-week low
- $2.88
- Avg volume (3M)
- —
- Shares outstanding
- 1.87M
- Employees
- 6
- Next earnings
- —
About Polyrizon Ltd.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
- ISIN
- IL0011814113
- Founded
- 2005
- Listed since
- Oct 29, 2024
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.